Eli Lilly announces Ajax Therapeutics acquisition for up to $2.3B
NewsBytes | April 28, 2026 12:40 AM CST
AJ1-11095 shows early promise
The heart of this deal is AJ1-11095, an oral drug from Ajax that is still in early testing but shows promise for patients who have not had much luck with other treatments.
Eli Lilly wants to share clinical results by 2026 and speed things up from there.
Lilly says they are excited about bringing something important to people fighting blood cancer.
READ NEXT
-
8 Delicious Snacks That Let You Cook Without Actually Cooking
-
4 members of a family died after eating watermelon? Are you also making this mistake? Know the doctor’s opinion
-
Make instant Masala Shakkarpara for guests, know the recipe
-
Why did the co-founder of Zoho request the youth of India to leave America and come to India?
-
Which was Rohit Sharma’s first car? Today the collection includes everything from Lamborghini to Mercedes – know how much is his net worth
